Want to see AU:TRJ full AI Analyst Report?
Top Page
Trajan Group Holdings Ltd
(Sydney:TRJ)
Select Model
Select Model
Rating:50Neutral
Price Target:
AU$0.32
▼(-17.95% Downside)
Action:Reiterated
Date:07/04/26
The score is primarily held back by weak profitability (net losses, negative ROE) and deteriorating free cash flow, alongside bearish technical trends (price below key moving averages and negative MACD). Modest revenue growth and a relatively stable balance sheet provide partial support but are not yet offsetting the operational and momentum headwinds.
Positive Factors
Recurring consumables business
Trajan's core business sells consumables and components used in routine testing, creating recurring demand from repeat purchases and embedded OEM channels. This consumables-led model supports predictable revenue streams and customer stickiness over the medium term.
Negative Factors
Negative net income / ROE
The company is reporting net losses and negative return on equity, which erodes shareholder value and limits internal capital for growth. Persisting losses can force reliance on external funding and constrain strategic investments over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables business
Trajan's core business sells consumables and components used in routine testing, creating recurring demand from repeat purchases and embedded OEM channels. This consumables-led model supports predictable revenue streams and customer stickiness over the medium term.
Read all positive factors
Trajan Group Holdings Ltd (TRJ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$45.09M
Dividend YieldN/A
Average Volume (3M)21.61K
Price to Earnings (P/E)―
Beta (1Y)0.70
Revenue Growth6.20%
EPS Growth95.19%
CountryAU
Employees600
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding152,863,630
10 Day Avg. Volume15,523
30 Day Avg. Volume21,606
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)1.03
Price to Sales (P/S)0.65
P/FCF Ratio16.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.83Price Target Upside111.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.06
Revenue Forecast (FY)AU$181.07M
Trajan Group Holdings Ltd Business Overview & Revenue Model
Company Description
Headquartered in Ringwood, Australia, and established in 2011, Trajan Group Holdings Limited is a global enterprise focused on designing, manufacturing, marketing, and distributing a diverse range of analytical and life science instruments and ass...
How the Company Makes Money
TRJ makes money primarily by selling analytical consumables, components, and related laboratory products used in routine and repeat testing workflows, where customers repurchase items as they are consumed or replaced. Additional revenue is generat...
Trajan Group Holdings Ltd Financial Statement Overview
Summary
Income Statement
55
Neutral
Balance Sheet
60
Neutral
Cash Flow
50
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 169.52M | 166.46M | 155.02M | 162.15M | 107.57M | 76.57M |
| Gross Profit | 42.31M | 63.47M | 59.75M | 22.93M | 42.63M | 28.48M |
| EBITDA | 6.69M | 8.14M | -20.36M | 14.16M | 5.14M | 3.46M |
| Net Income | -1.38M | -4.46M | -25.33M | 1.89M | 1.70M | 1.88M |
Balance Sheet | ||||||
| Total Assets | 192.32M | 195.63M | 188.00M | 229.04M | 206.78M | 99.38M |
| Cash, Cash Equivalents and Short-Term Investments | 12.78M | 11.85M | 11.24M | 11.04M | 13.16M | 51.72M |
| Total Debt | 69.37M | 55.49M | 56.16M | 61.30M | 66.18M | 17.02M |
| Total Liabilities | 89.27M | 90.01M | 85.15M | 99.51M | 90.27M | 33.30M |
| Stockholders Equity | 103.05M | 105.62M | 102.85M | 129.53M | 116.51M | 66.08M |
Cash Flow | ||||||
| Free Cash Flow | 1.46M | 6.74M | 6.43M | 998.00K | -1.28M | 8.34M |
| Operating Cash Flow | 4.47M | 10.83M | 9.47M | 9.55M | 2.13M | 9.45M |
| Investing Cash Flow | -3.02M | -4.09M | -3.04M | -8.55M | -116.38M | 402.00K |
| Financing Cash Flow | 1.57M | -5.64M | -6.40M | -3.36M | 74.69M | 36.81M |
Trajan Group Holdings Ltd Technical Analysis
Negative
0.39
Price Trends
0.30
Negative
0.38
Negative
0.54
Negative
Market Momentum
>-0.01
Negative
53.59
Neutral
81.15
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:TRJ, the sentiment is Negative. The current price of 0.39 is above the 20-day moving average (MA) of 0.25, above the 50-day MA of 0.30, and below the 200-day MA of 0.54, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 53.59 is Neutral, neither overbought nor oversold. The STOCH value of 81.15 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:TRJ.
Trajan Group Holdings Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | AU$1.00B | 47.86 | 9.57% | ― | 12.52% | 23.99% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$45.09M | -32.22 | -1.32% | ― | 6.20% | 95.19% | |
48 Neutral | AU$28.08M | -3.05 | -93.66% | ― | -23.71% | -16.02% | |
42 Neutral | AU$43.95M | 421.52 | 0.48% | ― | 24.45% | ― | |
42 Neutral | AU$13.16M | -2.24 | -29.05% | ― | 6.14% | -20.00% | |
40 Underperform | AU$15.45M | -1.29 | -23.93% | ― | 9.69% | 52.31% |
* Healthcare Sector Average
AU:TRJ
Trajan Group Holdings Ltd
0.29
-0.45
-60.54%
AU:CMP
Compumedics Limited
0.23
-0.07
-24.59%
AU:NAN
Nanosonics Limited
3.24
-0.50
-13.37%
AU:PIQ
Proteomics International Laboratories Ltd.
0.21
-0.27
-56.38%
AU:GSS
Genetic Signatures Ltd.
0.06
-0.31
-82.70%
AU:IDT
IDT Australia Limited
0.03
-0.07
-67.35%
Trajan Group Holdings Ltd Corporate Events
Trajan Group Updates Market on Lapse of 155,000 Conditional Options
Jul 2, 2026
Trajan Group Holdings Ltd has notified the market of changes to its capital structure, confirming that a series of conditional options, trading under the code TRJAA and tied to various expiry dates and exercise prices, have ceased. The lapse stems...
Trajan director Robert Lyon restructures equity holdings
Jun 2, 2026
Trajan Group Holdings has disclosed a change in the securities held by director Robert Lyon, detailing a rebalancing between his ordinary shareholding and unlisted options. The notice shows that Lyon’s direct ordinary shareholding increased ...
Trajan Group Seeks ASX Quotation for Additional 270,589 Shares
Jun 2, 2026
Trajan Group Holdings has applied for quotation on the ASX of 270,589 ordinary fully paid shares, effective 1 June 2026. The additional securities, arising from exercised options or converted instruments, modestly expand the company’s listed...
Trajan flags FX hit to FY26 results as cost initiatives boost margins
May 26, 2026
Trajan Group Holdings reports that market demand in the second half of FY26 is broadly in line with expectations, with continued growth on a fixed forex basis across components and consumables, capital equipment, and an accelerating disruptive tec...
Trajan Names Insider Simon Billingham Interim CFO to Support Leadership Transition
Apr 21, 2026
Trajan Group Holdings Limited, a global analytical science and device company specialising in life science tools for biological, food and environmental analysis, operates more than seven manufacturing sites across the U.S., Australia, Europe and M...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.